By Michael Gwarisa A once-weekly pill for HIV treatment has performed as well as standard daily therapy in two landmark Phase III clinical trials, bringing researchers a step closer to offering people living with HIV the world’s first complete once-weekly oral treatment regimen. The findings from the ISLEND-1 and ISLEND-2 studies will be presented at